Skip links

Corporate communications

PharmaCielo Announces Q3 2023 Financial Results

November 29, 2023 PharmaCielo Announces Q3 2023 Financial Results All figures in Canadian dollars ($) unless otherwise specified TORONTO and RIONEGRO, Colombia, November 29, 2023 – PharmaCielo Ltd. (“PharmaCielo” or the “Company“) (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer

pharmacielo

PharmaCielo Announces Q2 2023 Financial Results

August 29, 2023 PharmaCielo Announces Q2 2023 Financial Results All figures in Canadian dollars ($) unless otherwise specified TORONTO and RIONEGRO, Colombia, August 29, 2023 – PharmaCielo Ltd. (“PharmaCielo” or the “Company“) (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer

PharmaCielo Provides Corporate Update

August 10, 2023 TORONTO, Canada and RIONEGRO, Colombia (August 10, 2023) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. (“Holdings”), today provided

PharmaCielo Announces Appointment of Marc Lustig as Chairman and CEO

TORONTO, Canada and RIONEGRO, Colombia (July 11, 2023) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. (“Holdings”), today announced that Marc Lustig

PharmaCielo Provides Corporate Update

Jun 29, 2023 PharmaCielo Provides Corporate Update PharmaCielo is actively working with more than 24 customers in 15 countries globally, with a focus on psychoactive APIs and dried flower. The Company recently made its first shipment of THC Distillate and THC-Dominant Dried Flower to a

¿Why to invest in Pharmacielo?

July 24, 2023 One of the largest production capacities in the world at great efficiency and world wide presence . Unique cannabis genetics, deep cultivar library, expert agronomy and equatorial growing conditions . Pharma approach for consistent quality: GACP, ICANN GAP and EUGMP standards for

PharmaCielo Announces Q1 2023 Financial Results

May 29, 2023 The Company has products in various stages of testing and sales with more than 40 customers in 11 countries, with continued growth expected for the year. Q1 2023 revenue of $786,498; Adjusted EBITDA loss of $1.9 million. PharmaCielo continues to focus on